Arterial Stiffness Is Related to Systemic Inflammation in Essential Hypertension

The acute phase–reactant high-sensitivity C-reactive protein, a marker of vascular inflammation and an atherosclerotic risk factor, is related to arterial stiffness in healthy subjects and in systemic vasculitis. To explore the relationship between markers of inflammation, interleukin-6 (IL-6), tumo...

Full description

Saved in:
Bibliographic Details
Published inHypertension (Dallas, Tex. 1979) Vol. 46; no. 5; pp. 1118 - 1122
Main Authors Mahmud, Azra, Feely, John
Format Journal Article
LanguageEnglish
Published Philadelphia, PA American Heart Association, Inc 01.11.2005
Hagerstown, MD Lippincott
Subjects
Online AccessGet full text
ISSN0194-911X
1524-4563
1524-4563
DOI10.1161/01.HYP.0000185463.27209.b0

Cover

Loading…
Abstract The acute phase–reactant high-sensitivity C-reactive protein, a marker of vascular inflammation and an atherosclerotic risk factor, is related to arterial stiffness in healthy subjects and in systemic vasculitis. To explore the relationship between markers of inflammation, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and high-sensitivity C-reactive protein with arterial stiffness, we studied untreated patients (n=78; 56% male; 47±1 years of age; mean±SEM) with essential hypertension. After overnight fast, augmentation index and pulse wave velocity were assessed noninvasively and related to plasma levels of inflammatory markers measured by ELISA. Pulse wave velocity was significantly related to plasma high-sensitivity C-reactive protein (r=0.31; P<0.001), TNF-α, (r=0.30; P<0.001) and IL-6 (r=0.21; P<0.05). There was also a relationship between heart rate–corrected augmentation index to high-sensitivity C-reactive protein (r=0.37; P<0.001), IL-6 (r=0.24; P<0.05), and TNF-α (r=0.19, P=0.06). High-sensitivity C-reactive protein was an independent predictor of pulse wave velocity and augmentation index in a multiple stepwise regression model. High-sensitivity C-reactive protein, a marker of systemic inflammation, is independently related to pulse wave velocity, a marker of aortic stiffness, and augmentation index, a manifestation of wave reflection, in essential hypertension.
AbstractList The acute phase-reactant high-sensitivity C-reactive protein, a marker of vascular inflammation and an atherosclerotic risk factor, is related to arterial stiffness in healthy subjects and in systemic vasculitis. To explore the relationship between markers of inflammation, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and high-sensitivity C-reactive protein with arterial stiffness, we studied untreated patients (n=78; 56% male; 47+/-1 years of age; mean+/-SEM) with essential hypertension. After overnight fast, augmentation index and pulse wave velocity were assessed noninvasively and related to plasma levels of inflammatory markers measured by ELISA. Pulse wave velocity was significantly related to plasma high-sensitivity C-reactive protein (r=0.31; P<0.001), TNF-alpha, (r=0.30; P<0.001) and IL-6 (r=0.21; P<0.05). There was also a relationship between heart rate-corrected augmentation index to high-sensitivity C-reactive protein (r=0.37; P<0.001), IL-6 (r=0.24; P<0.05), and TNF-alpha (r=0.19, P=0.06). High-sensitivity C-reactive protein was an independent predictor of pulse wave velocity and augmentation index in a multiple stepwise regression model. High-sensitivity C-reactive protein, a marker of systemic inflammation, is independently related to pulse wave velocity, a marker of aortic stiffness, and augmentation index, a manifestation of wave reflection, in essential hypertension.
The acute phase–reactant high-sensitivity C-reactive protein, a marker of vascular inflammation and an atherosclerotic risk factor, is related to arterial stiffness in healthy subjects and in systemic vasculitis. To explore the relationship between markers of inflammation, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and high-sensitivity C-reactive protein with arterial stiffness, we studied untreated patients (n=78; 56% male; 47±1 years of age; mean±SEM) with essential hypertension. After overnight fast, augmentation index and pulse wave velocity were assessed noninvasively and related to plasma levels of inflammatory markers measured by ELISA. Pulse wave velocity was significantly related to plasma high-sensitivity C-reactive protein ( r =0.31; P <0.001), TNF-α, ( r =0.30; P <0.001) and IL-6 ( r =0.21; P <0.05). There was also a relationship between heart rate–corrected augmentation index to high-sensitivity C-reactive protein ( r =0.37; P <0.001), IL-6 ( r =0.24; P <0.05), and TNF-α ( r =0.19, P =0.06). High-sensitivity C-reactive protein was an independent predictor of pulse wave velocity and augmentation index in a multiple stepwise regression model. High-sensitivity C-reactive protein, a marker of systemic inflammation, is independently related to pulse wave velocity, a marker of aortic stiffness, and augmentation index, a manifestation of wave reflection, in essential hypertension.
The acute phase–reactant high-sensitivity C-reactive protein, a marker of vascular inflammation and an atherosclerotic risk factor, is related to arterial stiffness in healthy subjects and in systemic vasculitis. To explore the relationship between markers of inflammation, interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and high-sensitivity C-reactive protein with arterial stiffness, we studied untreated patients (n=78; 56% male; 47±1 years of age; mean±SEM) with essential hypertension. After overnight fast, augmentation index and pulse wave velocity were assessed noninvasively and related to plasma levels of inflammatory markers measured by ELISA. Pulse wave velocity was significantly related to plasma high-sensitivity C-reactive protein (r=0.31; P<0.001), TNF-α, (r=0.30; P<0.001) and IL-6 (r=0.21; P<0.05). There was also a relationship between heart rate–corrected augmentation index to high-sensitivity C-reactive protein (r=0.37; P<0.001), IL-6 (r=0.24; P<0.05), and TNF-α (r=0.19, P=0.06). High-sensitivity C-reactive protein was an independent predictor of pulse wave velocity and augmentation index in a multiple stepwise regression model. High-sensitivity C-reactive protein, a marker of systemic inflammation, is independently related to pulse wave velocity, a marker of aortic stiffness, and augmentation index, a manifestation of wave reflection, in essential hypertension.
The acute phase-reactant high-sensitivity C-reactive protein, a marker of vascular inflammation and an atherosclerotic risk factor, is related to arterial stiffness in healthy subjects and in systemic vasculitis. To explore the relationship between markers of inflammation, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and high-sensitivity C-reactive protein with arterial stiffness, we studied untreated patients (n=78; 56% male; 47+/-1 years of age; mean+/-SEM) with essential hypertension. After overnight fast, augmentation index and pulse wave velocity were assessed noninvasively and related to plasma levels of inflammatory markers measured by ELISA. Pulse wave velocity was significantly related to plasma high-sensitivity C-reactive protein (r=0.31; P<0.001), TNF-alpha, (r=0.30; P<0.001) and IL-6 (r=0.21; P<0.05). There was also a relationship between heart rate-corrected augmentation index to high-sensitivity C-reactive protein (r=0.37; P<0.001), IL-6 (r=0.24; P<0.05), and TNF-alpha (r=0.19, P=0.06). High-sensitivity C-reactive protein was an independent predictor of pulse wave velocity and augmentation index in a multiple stepwise regression model. High-sensitivity C-reactive protein, a marker of systemic inflammation, is independently related to pulse wave velocity, a marker of aortic stiffness, and augmentation index, a manifestation of wave reflection, in essential hypertension.The acute phase-reactant high-sensitivity C-reactive protein, a marker of vascular inflammation and an atherosclerotic risk factor, is related to arterial stiffness in healthy subjects and in systemic vasculitis. To explore the relationship between markers of inflammation, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and high-sensitivity C-reactive protein with arterial stiffness, we studied untreated patients (n=78; 56% male; 47+/-1 years of age; mean+/-SEM) with essential hypertension. After overnight fast, augmentation index and pulse wave velocity were assessed noninvasively and related to plasma levels of inflammatory markers measured by ELISA. Pulse wave velocity was significantly related to plasma high-sensitivity C-reactive protein (r=0.31; P<0.001), TNF-alpha, (r=0.30; P<0.001) and IL-6 (r=0.21; P<0.05). There was also a relationship between heart rate-corrected augmentation index to high-sensitivity C-reactive protein (r=0.37; P<0.001), IL-6 (r=0.24; P<0.05), and TNF-alpha (r=0.19, P=0.06). High-sensitivity C-reactive protein was an independent predictor of pulse wave velocity and augmentation index in a multiple stepwise regression model. High-sensitivity C-reactive protein, a marker of systemic inflammation, is independently related to pulse wave velocity, a marker of aortic stiffness, and augmentation index, a manifestation of wave reflection, in essential hypertension.
Author Feely, John
Mahmud, Azra
AuthorAffiliation From the Department of Therapeutics and Hypertension Clinic, Trinity Centre for Health Sciences, St. James’s Hospital, Dublin 8, Ireland
AuthorAffiliation_xml – name: From the Department of Therapeutics and Hypertension Clinic, Trinity Centre for Health Sciences, St. James’s Hospital, Dublin 8, Ireland
Author_xml – sequence: 1
  givenname: Azra
  surname: Mahmud
  fullname: Mahmud, Azra
  organization: From the Department of Therapeutics and Hypertension Clinic, Trinity Centre for Health Sciences, St. James’s Hospital, Dublin 8, Ireland
– sequence: 2
  givenname: John
  surname: Feely
  fullname: Feely, John
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17255688$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/16216991$$D View this record in MEDLINE/PubMed
BookMark eNqNkV9rFDEUxYNU7Lb6FWQQ9G3W3JkkM-OTpdTuQsFiFfQp3Jm9odFMZk2ylP32Zv_Ugk_m5ULu75yEc87YiZ88MfYG-BxAwXsO88WP2znPB1opVD2vmop3854_YzOQlSiFVPUJm3HoRNkBfD9lZzH-zLgQonnBTkFVoLoOZuz2IiQKFl1xl6wxnmIslrH4Qg4TrYo0FXfbmGi0Q7H0xuE4YrKTL6wvrmIkn3bSxXZN2cbHvHnJnht0kV4d5zn79unq6-WivPl8vby8uCkHmf9dVqKtSSoY-h7aWvKV7HrsuWqV6CWiQAKusEdoO4Om5o0kIxrJ802Dwgz1OXt38F2H6feGYtKjjQM5h56mTdSqbWpZdZDB10dw04-00utgRwxb_ZhBBt4eAYwDOhPQDzY-cU0lpWrbzH08cEOYYgxk9GDTPo0U0DoNXO_q0Rx0rkc_1aP39eieZ4sP_1j8feV_xOIgfphc7iz-cpsHCvqe0KX7vUJUqi0rziXALuOdB6__AIWxpFI
CODEN HPRTDN
CitedBy_id crossref_primary_10_1111_j_1524_6175_2007_07400_x
crossref_primary_10_1093_ajh_hpt238
crossref_primary_10_1177_1759720X10384307
crossref_primary_10_1016_j_idairyj_2007_03_002
crossref_primary_10_1097_HJH_0000000000002678
crossref_primary_10_1177_1358863X14556695
crossref_primary_10_1902_jop_2009_097001
crossref_primary_10_1161_HYPERTENSIONAHA_110_163444
crossref_primary_10_1161_HYPERTENSIONAHA_120_16915
crossref_primary_10_1097_01_gme_0000243575_09065_48
crossref_primary_10_1186_s12872_022_02773_9
crossref_primary_10_1016_j_exger_2019_110650
crossref_primary_10_1016_j_artres_2012_09_003
crossref_primary_10_1016_j_trsl_2017_10_011
crossref_primary_10_1186_s12877_015_0089_x
crossref_primary_10_1016_j_numecd_2008_07_006
crossref_primary_10_3389_fcvm_2023_1278795
crossref_primary_10_1016_j_amjcard_2008_10_004
crossref_primary_10_1016_j_lfs_2014_12_001
crossref_primary_10_1016_S1875_2136_08_70253_5
crossref_primary_10_1093_ajh_hpt103
crossref_primary_10_1111_j_1445_5994_2008_01811_x
crossref_primary_10_14814_phy2_14920
crossref_primary_10_5551_jat_13516
crossref_primary_10_3389_fcvm_2022_818890
crossref_primary_10_1253_circj_CJ_11_1506
crossref_primary_10_1093_ndt_gfq806
crossref_primary_10_1007_s12170_008_0025_0
crossref_primary_10_1016_j_ijcard_2009_04_027
crossref_primary_10_3390_medicina57070653
crossref_primary_10_1080_13813455_2020_1764049
crossref_primary_10_1097_gme_0b013e31821f81c2
crossref_primary_10_1152_physrev_00003_2017
crossref_primary_10_2174_1871520623666230727095154
crossref_primary_10_1093_ajh_hpy145
crossref_primary_10_1364_BOE_457617
crossref_primary_10_1016_j_rmed_2009_09_004
crossref_primary_10_1038_sj_ejcn_1602886
crossref_primary_10_1093_ndt_gfk054
crossref_primary_10_1038_jhh_2010_23
crossref_primary_10_1016_j_artres_2009_09_001
crossref_primary_10_2169_internalmedicine_51_7701
crossref_primary_10_7600_jpfsm_1_205
crossref_primary_10_4103_tcmj_tcmj_60_24
crossref_primary_10_1016_j_ancard_2011_07_008
crossref_primary_10_1113_jphysiol_2006_111260
crossref_primary_10_1152_ajpheart_00043_2016
crossref_primary_10_1364_BOE_520551
crossref_primary_10_1111_ene_12332
crossref_primary_10_1016_j_atherosclerosis_2006_05_025
crossref_primary_10_2165_11593790_000000000_00000
crossref_primary_10_1016_j_cca_2007_06_009
crossref_primary_10_1038_jhh_2017_7
crossref_primary_10_1186_s12944_018_0671_2
crossref_primary_10_1053_j_semvascsurg_2015_04_003
crossref_primary_10_1016_j_artres_2007_03_005
crossref_primary_10_1093_ndt_gfl019
crossref_primary_10_1016_j_artres_2007_03_001
crossref_primary_10_1086_677370
crossref_primary_10_1111_jch_12533
crossref_primary_10_1109_JSEN_2016_2582805
crossref_primary_10_1111_jnc_14235
crossref_primary_10_3109_08037051_2010_532323
crossref_primary_10_1016_j_ymthe_2018_06_001
crossref_primary_10_1016_j_oraloncology_2020_104711
crossref_primary_10_1177_00033197211065795
crossref_primary_10_1080_10715762_2016_1201816
crossref_primary_10_1093_eurheartj_ehy310
crossref_primary_10_1016_j_hjc_2017_12_010
crossref_primary_10_1016_j_lfs_2017_03_016
crossref_primary_10_1253_circj_71_348
crossref_primary_10_1177_0003319712447888
crossref_primary_10_1053_j_ackd_2007_03_006
crossref_primary_10_1152_japplphysiol_00151_2014
crossref_primary_10_1016_j_amjcard_2009_05_002
crossref_primary_10_1111_jch_13297
crossref_primary_10_1016_j_vph_2018_12_005
crossref_primary_10_1038_ajh_2011_119
crossref_primary_10_1002_art_24521
crossref_primary_10_1097_01_hjh_0000249701_49854_21
crossref_primary_10_3109_10641963_2015_1081211
crossref_primary_10_1152_ajplung_00407_2020
crossref_primary_10_1016_j_atherosclerosis_2010_03_020
crossref_primary_10_1038_jhh_2011_59
crossref_primary_10_1007_s10741_019_09860_8
crossref_primary_10_1038_ki_2012_131
crossref_primary_10_1016_j_rvm_2016_12_001
crossref_primary_10_1038_sj_jhh_1002168
crossref_primary_10_1097_HJH_0000000000000444
crossref_primary_10_1097_HJH_0000000000001413
crossref_primary_10_1016_j_ejphar_2010_02_018
crossref_primary_10_1016_j_jash_2007_09_003
crossref_primary_10_1177_00033197211034267
crossref_primary_10_1007_s12170_010_0151_3
crossref_primary_10_1038_hr_2010_12
crossref_primary_10_1038_s41440_021_00716_z
crossref_primary_10_1038_hr_2015_22
crossref_primary_10_3390_life12030397
crossref_primary_10_4178_epih_e2014005
crossref_primary_10_15421_022082
crossref_primary_10_1080_08164622_2021_1964332
crossref_primary_10_1038_s41569_019_0178_1
crossref_primary_10_1093_ajh_hpw209
crossref_primary_10_1093_ckj_sfae258
crossref_primary_10_1016_j_artres_2014_04_003
crossref_primary_10_1371_journal_pone_0183747
crossref_primary_10_3109_08037051_2014_940710
crossref_primary_10_1038_ajh_2010_246
crossref_primary_10_1016_j_ultrasmedbio_2017_04_026
crossref_primary_10_5551_jat_63801
crossref_primary_10_2147_VHRM_S294767
crossref_primary_10_1186_s12872_016_0268_5
crossref_primary_10_5494_wjh_v4_i1_1
crossref_primary_10_3899_jrheum_130520
crossref_primary_10_1038_s41371_021_00553_0
crossref_primary_10_1038_jhh_2015_105
crossref_primary_10_1111_j_1559_4564_2007_06006_x
crossref_primary_10_1134_S2079057017010167
crossref_primary_10_1007_s00467_017_3660_1
crossref_primary_10_4070_kcj_2013_43_2_73
crossref_primary_10_1038_ajh_2009_132
crossref_primary_10_1016_j_ijcard_2008_08_005
crossref_primary_10_1111_j_1755_5922_2008_00051_x
crossref_primary_10_15825_1995_1191_2024_3_117_123
crossref_primary_10_25040_aml2017_03_072
crossref_primary_10_1186_s40885_016_0039_8
crossref_primary_10_1111_nep_12859
crossref_primary_10_3389_fpubh_2020_600427
crossref_primary_10_3899_jrheum_130394
crossref_primary_10_1186_1476_9255_6_16
crossref_primary_10_1007_s11033_019_04690_1
crossref_primary_10_3390_jcm10143008
crossref_primary_10_1097_HJH_0b013e3280eec79f
crossref_primary_10_1038_hr_2009_71
crossref_primary_10_1016_j_bbi_2020_09_001
crossref_primary_10_1080_17474086_2021_1959316
crossref_primary_10_1016_j_maturitas_2014_04_012
crossref_primary_10_1016_j_atherosclerosis_2010_12_023
crossref_primary_10_3390_antiox10122026
crossref_primary_10_3899_jrheum_131110
crossref_primary_10_1097_MNH_0b013e328335eec9
crossref_primary_10_1586_erc_11_140
crossref_primary_10_2170_physiolsci_RP010707
crossref_primary_10_1111_iji_12342
crossref_primary_10_1002_acr_22340
crossref_primary_10_3390_jcm11247311
crossref_primary_10_1016_j_atherosclerosis_2009_08_047
crossref_primary_10_1038_sj_jhh_1002244
crossref_primary_10_1038_sj_ejcn_1602577
crossref_primary_10_3889_oamjms_2016_011
crossref_primary_10_1093_ije_dyn374
crossref_primary_10_1515_jpem_2023_0530
crossref_primary_10_3390_ijms20163942
crossref_primary_10_1038_hr_2016_35
crossref_primary_10_1016_j_vph_2023_107214
crossref_primary_10_1111_1756_185X_14148
crossref_primary_10_1507_endocrj_EJ17_0117
crossref_primary_10_3109_17435390_2011_611915
crossref_primary_10_1161_JAHA_117_006535
crossref_primary_10_1097_HJH_0000000000002390
crossref_primary_10_1111_jch_13002
crossref_primary_10_4070_kcj_2007_37_7_312
crossref_primary_10_1080_08037050701464443
crossref_primary_10_3390_ijerph19053062
crossref_primary_10_1002_prp2_1189
crossref_primary_10_1161_ATVBAHA_116_308563
crossref_primary_10_1007_s00408_015_9804_9
crossref_primary_10_1111_j_1440_1681_2008_05062_x
crossref_primary_10_1161_JAHA_120_017598
crossref_primary_10_3109_08860221003664280
crossref_primary_10_1016_j_atherosclerosis_2010_08_065
crossref_primary_10_1038_hr_2010_82
crossref_primary_10_1038_jhh_2009_8
crossref_primary_10_1038_jhh_2009_7
crossref_primary_10_1016_j_hfc_2011_08_002
crossref_primary_10_1007_s10659_020_09809_1
crossref_primary_10_1038_jhh_2013_17
crossref_primary_10_1016_j_diabet_2011_07_006
crossref_primary_10_1111_j_1751_7176_2008_00002_x
crossref_primary_10_1038_hr_2009_91
crossref_primary_10_5551_jat_2741
crossref_primary_10_3390_nu12102982
crossref_primary_10_31083_j_fbl2909320
crossref_primary_10_5301_jbm_5000049
crossref_primary_10_1007_s11154_020_09616_y
crossref_primary_10_1161_HYPERTENSIONAHA_120_15184
crossref_primary_10_3349_ymj_2012_53_2_258
crossref_primary_10_1038_jhh_2009_17
crossref_primary_10_1038_s41430_021_00870_0
crossref_primary_10_1111_j_1365_2125_2007_02980_x
crossref_primary_10_1097_MBP_0b013e32832941ea
crossref_primary_10_1097_HJH_0b013e3280a94e76
crossref_primary_10_1097_HJH_0b013e3282dc25da
crossref_primary_10_1002_ptr_6046
crossref_primary_10_1186_s12950_014_0029_0
crossref_primary_10_1093_ckj_sfx120
crossref_primary_10_1186_s12872_021_02180_6
crossref_primary_10_1155_2017_9632846
crossref_primary_10_1093_ajh_hpw134
crossref_primary_10_2174_1570161120666220201160038
crossref_primary_10_1111_j_1472_8206_2008_00584_x
crossref_primary_10_1161_JAHA_118_010329
crossref_primary_10_1002_dmrr_3495
crossref_primary_10_1007_s00439_007_0349_8
crossref_primary_10_1177_0004563217733286
crossref_primary_10_3389_fcvm_2021_709396
crossref_primary_10_1016_j_jash_2016_07_006
crossref_primary_10_1186_s13063_019_3690_z
crossref_primary_10_1097_HJH_0b013e32833ca68c
crossref_primary_10_1016_j_bspc_2012_03_001
crossref_primary_10_1097_00029330_200607020_00016
crossref_primary_10_1007_s40520_019_01274_8
crossref_primary_10_1002_ijc_30839
crossref_primary_10_1902_jop_2009_080471
crossref_primary_10_1186_s12891_016_1201_x
crossref_primary_10_1161_CIRCRESAHA_115_306656
crossref_primary_10_1097_FJC_0000000000000017
crossref_primary_10_1016_j_bbi_2007_04_003
crossref_primary_10_2147_IJGM_S353276
crossref_primary_10_1161_JAHA_116_004987
crossref_primary_10_1364_BOE_557984
crossref_primary_10_17116_terarkh201688593_101
crossref_primary_10_1152_ajpregu_00168_2006
crossref_primary_10_1093_ajh_hpx007
crossref_primary_10_1016_j_bbi_2008_01_009
crossref_primary_10_2991_artres_k_191114_002
crossref_primary_10_1159_000374095
crossref_primary_10_1152_ajpheart_00287_2022
crossref_primary_10_1016_j_envres_2018_02_008
crossref_primary_10_1111_j_1524_6175_2006_06032_x
crossref_primary_10_1016_j_smrv_2012_03_002
crossref_primary_10_1152_ajpheart_00328_2013
crossref_primary_10_1016_j_ijcard_2022_02_033
crossref_primary_10_2337_dc11_1475
Cites_doi 10.1161/01.cir.0000033824.02722.f7
10.1016/j.atherosclerosis.2004.04.014
10.1038/sj.jhh.1001786
10.1016/j.metabol.2004.05.013
10.1056/NEJMoa040967
10.1161/01.str.0000130422.89335.81
10.1161/01.CIR.0000105767.94169.E3
10.1111/j.1469-7793.2000.t01-1-00263.x
10.3317/jraas.2004.025
10.1097/00004872-200402000-00019
10.1016/S0895-7061(01)02313-5
10.1161/circ.102.9.1000
10.1046/j.1365-2125.2002.1528adoc.x
10.1038/sj.jhh.1001785
10.1161/circ.102.9.994
10.1016/j.cpcardiol.2004.03.004
10.1210/jc.2003-032103
10.1081/CEH-200031959
10.1056/NEJMoa042378
10.1097/00004872-199917020-00008
10.1161/hyp.38.3.434
10.1161/01.str.0000099124.84425.bb
10.1161/atvb.19.4.972
10.1161/01.hyp.0000111829.46090.92
10.1016/S0021-9150(03)00158-8
10.1161/hyp.38.3.399
10.1016/S0895-7061(00)01320-0
10.1002/art.20002
10.1016/j.amjhyper.2003.12.002
10.1161/hyp.37.5.1236
10.1161/01.atv.0000151373.33830.41
10.1161/01.atv.zhq0504.0173
ContentType Journal Article
Copyright 2005 American Heart Association, Inc.
2006 INIST-CNRS
Copyright_xml – notice: 2005 American Heart Association, Inc.
– notice: 2006 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1161/01.HYP.0000185463.27209.b0
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
CrossRef

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1524-4563
EndPage 1122
ExternalDocumentID 16216991
17255688
10_1161_01_HYP_0000185463_27209_b0
00004268-200511000-00010
Genre Journal Article
GroupedDBID ---
.-D
.3C
.55
.GJ
.XZ
.Z2
01R
0R~
18M
1J1
2WC
3O-
40H
4Q1
4Q2
4Q3
53G
5GY
5RE
5VS
71W
77Y
7O~
AAAAV
AAAXR
AAFWJ
AAGIX
AAHPQ
AAIQE
AAJCS
AAMOA
AAMTA
AAQKA
AARTV
AASCR
AASOK
AAXQO
AAYEP
ABASU
ABBUW
ABDIG
ABJNI
ABOCM
ABPXF
ABQRW
ABVCZ
ABXVJ
ABXYN
ABZAD
ABZZY
ACCJW
ACDDN
ACEWG
ACGFO
ACGFS
ACILI
ACLDA
ACWDW
ACWRI
ACXJB
ACXNZ
ACZKN
ADBBV
ADFPA
ADGGA
ADHPY
ADNKB
AE3
AE6
AEBDS
AEETU
AENEX
AFBFQ
AFDTB
AFEXH
AFFNX
AFNMH
AFUWQ
AGINI
AHMBA
AHOMT
AHQNM
AHQVU
AHRYX
AHVBC
AIJEX
AINUH
AJCLO
AJIOK
AJNWD
AJNYG
AJZMW
AKCTQ
AKULP
ALKUP
ALMA_UNASSIGNED_HOLDINGS
ALMTX
AMJPA
AMKUR
AMNEI
AOHHW
AOQMC
BAWUL
BCGUY
BOYCO
BQLVK
BS7
C1A
C45
CS3
DIK
DIWNM
DUNZO
E.X
E3Z
EBS
EEVPB
EJD
ERAAH
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
FL-
FW0
GNXGY
GQDEL
GX1
H0~
H13
HLJTE
HZ~
IKREB
IKYAY
IN~
IPNFZ
JF9
JG8
JK3
JK8
K-A
K-F
K8S
KD2
KMI
KQ8
L-C
L7B
N4W
N9A
N~7
N~B
N~M
O9-
OAG
OAH
OB3
OCUKA
ODA
ODMTH
OGROG
OHYEH
OK1
OL1
OLG
OLH
OLU
OLV
OLY
OLZ
OPUJH
ORVUJ
OUVQU
OVD
OVDNE
OVIDH
OVLEI
OWBYB
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P-K
P2P
PQQKQ
R58
RAH
RIG
RLZ
S4R
S4S
T8P
TEORI
TR2
TSPGW
V2I
VVN
W3M
W8F
WH7
WOQ
WOW
X3V
X3W
X7M
XXN
XYM
YFH
YHZ
YOC
YYM
YYP
ZFV
ZGI
ZZMQN
AAYXX
ADGHP
CITATION
IQODW
OZ-
ACIJW
AWKKM
CGR
CUY
CVF
ECM
EIF
NPM
OLW
RHF
7X8
ID FETCH-LOGICAL-c5000-2483e561cbb18350d59bab06864b5aa4ae106aba189faf3075ef4750ba17a4fc3
ISSN 0194-911X
1524-4563
IngestDate Thu Aug 07 15:12:50 EDT 2025
Wed Feb 19 01:42:27 EST 2025
Mon Jul 21 09:16:54 EDT 2025
Thu Apr 24 23:04:35 EDT 2025
Tue Jul 01 04:30:38 EDT 2025
Fri May 16 03:51:29 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords Human
Hypertension
Scanning electron microscopy
Elasticity
arteries
Cardiovascular disease
Inflammation
hypertension, arterial
Endothelium
Vascular disease
Interleukin 6
Heart rate
Tumor necrosis factor
Atherosclerosis
Risk factor
Aorta
Stiffness
C reactive protein
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c5000-2483e561cbb18350d59bab06864b5aa4ae106aba189faf3075ef4750ba17a4fc3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PMID 16216991
PQID 68735291
PQPubID 23479
PageCount 5
ParticipantIDs proquest_miscellaneous_68735291
pubmed_primary_16216991
pascalfrancis_primary_17255688
crossref_citationtrail_10_1161_01_HYP_0000185463_27209_b0
crossref_primary_10_1161_01_HYP_0000185463_27209_b0
wolterskluwer_health_00004268-200511000-00010
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2005-November
PublicationDateYYYYMMDD 2005-11-01
PublicationDate_xml – month: 11
  year: 2005
  text: 2005-November
PublicationDecade 2000
PublicationPlace Philadelphia, PA
Hagerstown, MD
PublicationPlace_xml – name: Philadelphia, PA
– name: Hagerstown, MD
– name: United States
PublicationTitle Hypertension (Dallas, Tex. 1979)
PublicationTitleAlternate Hypertension
PublicationYear 2005
Publisher American Heart Association, Inc
Lippincott
Publisher_xml – name: American Heart Association, Inc
– name: Lippincott
References e_1_3_1_21_2
e_1_3_1_22_2
e_1_3_1_23_2
e_1_3_1_24_2
e_1_3_1_8_2
e_1_3_1_7_2
e_1_3_1_9_2
e_1_3_1_20_2
e_1_3_1_4_2
e_1_3_1_29_2
e_1_3_1_3_2
e_1_3_1_6_2
e_1_3_1_5_2
e_1_3_1_25_2
e_1_3_1_26_2
e_1_3_1_2_2
e_1_3_1_27_2
e_1_3_1_1_2
e_1_3_1_28_2
(e_1_3_1_12_2) 2005; 22
e_1_3_1_32_2
e_1_3_1_33_2
e_1_3_1_13_2
e_1_3_1_11_2
e_1_3_1_30_2
e_1_3_1_10_2
e_1_3_1_31_2
e_1_3_1_17_2
e_1_3_1_16_2
e_1_3_1_15_2
e_1_3_1_14_2
e_1_3_1_19_2
e_1_3_1_18_2
References_xml – ident: e_1_3_1_2_2
  doi: 10.1161/01.cir.0000033824.02722.f7
– ident: e_1_3_1_26_2
  doi: 10.1016/j.atherosclerosis.2004.04.014
– ident: e_1_3_1_31_2
  doi: 10.1038/sj.jhh.1001786
– ident: e_1_3_1_32_2
  doi: 10.1016/j.metabol.2004.05.013
– ident: e_1_3_1_9_2
  doi: 10.1056/NEJMoa040967
– ident: e_1_3_1_7_2
  doi: 10.1161/01.str.0000130422.89335.81
– ident: e_1_3_1_5_2
  doi: 10.1161/01.CIR.0000105767.94169.E3
– ident: e_1_3_1_14_2
  doi: 10.1111/j.1469-7793.2000.t01-1-00263.x
– ident: e_1_3_1_20_2
  doi: 10.3317/jraas.2004.025
– ident: e_1_3_1_8_2
  doi: 10.1097/00004872-200402000-00019
– ident: e_1_3_1_27_2
  doi: 10.1016/S0895-7061(01)02313-5
– ident: e_1_3_1_22_2
  doi: 10.1161/circ.102.9.1000
– ident: e_1_3_1_25_2
  doi: 10.1046/j.1365-2125.2002.1528adoc.x
– ident: e_1_3_1_10_2
  doi: 10.1038/sj.jhh.1001785
– ident: e_1_3_1_21_2
  doi: 10.1161/circ.102.9.994
– ident: e_1_3_1_24_2
  doi: 10.1016/j.cpcardiol.2004.03.004
– ident: e_1_3_1_30_2
  doi: 10.1210/jc.2003-032103
– ident: e_1_3_1_15_2
  doi: 10.1081/CEH-200031959
– ident: e_1_3_1_33_2
  doi: 10.1056/NEJMoa042378
– volume: 22
  start-page: 1133
  year: 2005
  ident: e_1_3_1_12_2
  publication-title: J Hypertens
– ident: e_1_3_1_3_2
  doi: 10.1097/00004872-199917020-00008
– ident: e_1_3_1_4_2
  doi: 10.1161/hyp.38.3.434
– ident: e_1_3_1_29_2
  doi: 10.1161/01.str.0000099124.84425.bb
– ident: e_1_3_1_17_2
  doi: 10.1161/atvb.19.4.972
– ident: e_1_3_1_18_2
  doi: 10.1161/01.hyp.0000111829.46090.92
– ident: e_1_3_1_28_2
  doi: 10.1016/S0021-9150(03)00158-8
– ident: e_1_3_1_6_2
  doi: 10.1161/hyp.38.3.399
– ident: e_1_3_1_16_2
  doi: 10.1016/S0895-7061(00)01320-0
– ident: e_1_3_1_13_2
  doi: 10.1002/art.20002
– ident: e_1_3_1_23_2
  doi: 10.1016/j.amjhyper.2003.12.002
– ident: e_1_3_1_1_2
  doi: 10.1161/hyp.37.5.1236
– ident: e_1_3_1_19_2
  doi: 10.1161/01.atv.0000151373.33830.41
– ident: e_1_3_1_11_2
  doi: 10.1161/01.atv.zhq0504.0173
SSID ssj0014447
Score 2.3507981
Snippet The acute phase–reactant high-sensitivity C-reactive protein, a marker of vascular inflammation and an atherosclerotic risk factor, is related to arterial...
The acute phase-reactant high-sensitivity C-reactive protein, a marker of vascular inflammation and an atherosclerotic risk factor, is related to arterial...
SourceID proquest
pubmed
pascalfrancis
crossref
wolterskluwer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1118
SubjectTerms Arterial hypertension. Arterial hypotension
Arteries - physiopathology
Biological and medical sciences
Biomarkers - blood
Blood and lymphatic vessels
Blood Flow Velocity
C-Reactive Protein - metabolism
Cardiology. Vascular system
Clinical manifestations. Epidemiology. Investigative techniques. Etiology
Cross-Sectional Studies
Elasticity
Experimental diseases
Female
Humans
Hypertension - complications
Inflammation - blood
Inflammation - etiology
Inflammation - physiopathology
Interleukin-6 - blood
Male
Medical sciences
Middle Aged
Pulse
Tumor Necrosis Factor-alpha - metabolism
Title Arterial Stiffness Is Related to Systemic Inflammation in Essential Hypertension
URI https://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=fulltext&D=ovft&AN=00004268-200511000-00010
https://www.ncbi.nlm.nih.gov/pubmed/16216991
https://www.proquest.com/docview/68735291
Volume 46
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zj9MwELZgkRASQtyUY8kDbyglTmwnfqzYrsJRtA9bqftk2aktIlC7arra1f56xkeOoiIWXqLWrXN4JuNvxvONEXqnWVaBLwveCa3AQUllHgOqxnFKwSKnyoJWy0aefWPlnHxe0EXPPXHskq0aV9d7eSX_I1VoA7laluw_SLY7KTTAZ5AvHEHCcLyRjCc2H9MzPmpjnNGqG09PARwJqNLXaa4rm3MFovc0RVclpLGkI9v1OziiG5fGHgQUkGo5aLcw9MhG3H1Okb4av8c854MowmxSzuZHztBcbzpLfzydfj3bSfht4ws0EO26-EJXJ2IYheTEWsnF0IyGSGI9XKh2NhGsaTGYXwHgpfttN8OOjzAuz05cWUmAEoRlY7tSzMcq6WesdpX-t4msSy8EUGYLqxW30Z00z_3q_acv3eISISSw6P1ThFq0cP0Pf776Dm65fy4beIWM3_tkn3MC_7lc23yH5oejOwxAy-lD9CB4G9HEq84jdEuvHqO7s5BP8QSdtBoUdRoU1U0UNCjarqNWg6KhBsGXqNOgaKhBT9H8eHr6sYzDHhtxZbfCiFNSZBowdKUUGHeaLClXUlneEFFUSiI1TphUEhfcSAMTAtWGAMqEllwSU2XP0MFqvdIvUKRMCmjWYJ1jA25wVihCNFvyJRj5RDE-QrwdQVGFAvR2H5SfwjmiDIsECxh90Y--cKMvVDJCWdf33JdhuVGvwx1B9V2DgozQ21ZyAsyqXSuTK72-aASDB6ApxyP03Au078tSzLj9Jd6RsPDEZXcfAHudpaK2IKOr3ICTl3-7mVfoXv_-vUYH282FfgOId6sOnf7-Aq8Zovo
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Arterial+stiffness+is+related+to+systemic+inflammation+in+essential+hypertension&rft.jtitle=Hypertension+%28Dallas%2C+Tex.+1979%29&rft.au=MAHMUD%2C+Azra&rft.au=FEELY%2C+John&rft.date=2005-11-01&rft.pub=Lippincott&rft.issn=0194-911X&rft.volume=46&rft.issue=5&rft.spage=1118&rft.epage=1122&rft_id=info:doi/10.1161%2F01.HYP.0000185463.27209.b0&rft.externalDBID=n%2Fa&rft.externalDocID=17255688
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0194-911X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0194-911X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0194-911X&client=summon